Article
Multidisciplinary Sciences
Mikiyas Amare Getu, Panpan Wang, Eva Johanna Kantelhardt, Edom Seife, Changying Chen, Adamu Addissie
Summary: This study aimed to examine the validity and reliability of the EORTC QLQ-BR45 questionnaire among breast cancer patients in Ethiopia. The results showed that the questionnaire has good reliability and validity, and can be used to assess the quality of life of breast cancer patients.
SCIENTIFIC REPORTS
(2022)
Article
Endocrinology & Metabolism
Dennis Zetner, Claus Kamby, Sengul Gulen, Camilla Christophersen, Cecilie B. Paulsen, Emily Piga, Bodil Hoffmeyer, Faisal Mahmood, Jacob Rosenberg
Summary: This study aimed to investigate the impact of topical melatonin during radiation therapy on the quality of life in primary breast cancer patients. A total of 65 patients were included in the study, with 26 in the melatonin group and 22 in the placebo group. The results showed that while there was no difference in breast symptom scores on the last day of radiation, the melatonin group had significantly lower scores over the entire duration of the trial.
JOURNAL OF PINEAL RESEARCH
(2023)
Article
Oncology
R. E. Asberg, M. Nilsen, M. J. Hjermstad, K. V. Reinertsen, J. Karlsen, G. F. Giskeodegard, R. J. Reidunsdatter
Summary: The objective of this study was to provide normative values for the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires QLQ-C30, QLQ-SHQ22, QLQ-BR23, and QLQ-BR45 in the Norwegian general population. A random nationwide sample was drawn, and participants were notified through online health services and postal mail. The results showed that women and individuals with morbidities reported lower functioning and higher symptom burden. The study highlights the importance of considering age, sex, and morbidity when assessing health-related quality of life.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Cardiac & Cardiovascular Systems
Markus S. Anker, Sophia K. Potthoff, Alessia Lena, Jan Porthun, Sara Hadzibegovic, Ruben Evertz, Corinna Denecke, Ann-Kathrin Froehlich, Frederike Sonntag, Vera Regitz-Zagrosek, Stuart D. Rosen, Alexander R. Lyon, Thomas F. Luescher, John A. Spertus, Stefan D. Anker, Mahir Karakas, Lars Bullinger, Ulrich Keller, Ulf Landmesser, Javed Butler, Stephan von Haehling
Summary: This study compared the EORTC QLQ-C30 and ESC HeartQoL questionnaires for assessing health-related quality of life in cancer patients, and found that both instruments were associated with increased mortality in cancer patients. Combining both questionnaires provided even greater stratification of patient risk.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Medicine, General & Internal
Rachel S. van Leeuwaarde, Angelica M. Gonzalez-Clavijo, Marc Pracht, Galina Emelianova, Winson Y. Cheung, Christina Thirlwell, Kjell Oberg, Francesca Spada
Summary: This study aims to assess patients' perceptions of the EORTC QLQ-C30 and EORTC QLQ-G.I.NET21 questionnaires in neuroendocrine neoplasms (NENs). The study found that there are limitations in the design of the questions and the patients' satisfaction reporting of the questionnaire.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Nern Hoong Kao, N. Gopalakrishna Iyer, Alice Chua, Rahul Harshad Nagadia
Summary: This study evaluated the quality of life of head and neck cancer survivors after surgical treatment, specifically focusing on eating-related concerns. Factors such as advanced tumor stage, extent of surgery, and adjuvant treatment were found to be associated with lower overall health scores. Improvement in quality of life was observed in previous studies after one year.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Environmental Sciences
Robert Sloniewski, Marta Dabrowska-Bender, Urszula Religioni, Adam Fronczak, Anna Staniszewska, Aneta Duda-Zalewska, Magdalena Milewska, Magdalena Kedzierska, Rafal Adam Matkowski, Grazyna Dykowska, Anna Sloniewska, Anna Kupiecka
Summary: This study analyzed changes in the quality of life of women with ovarian and breast cancer after surgical treatment and adjuvant cancer therapy. The results showed that breast cancer patients rated their health and quality of life higher than ovarian cancer patients, but the differences were not statistically significant. The patients' health status had a clinically significant impact on their family and social life.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Article
Oncology
Carlos H. Barrios, Shigehira Saji, Nadia Harbeck, Hong Zhang, Kyung H. Jung, Sheetal Patel, Shilpen Patel, Anh Nguyen Duc, Mario Liste-Hermoso, Stephen Y. Chui, Elizabeth A. Mittendorf
Summary: This study assessed patients' experience of treatment burden when adding atezolizumab to neoadjuvant chemotherapy for early-stage TNBC. The results showed that adding atezolizumab did not impose additional treatment burden on patients while improving pathologic complete response.
Article
Oncology
O. Sjokvist, S. Hakansson, E. Pantiora, A. Karakatsanis
Summary: The study revealed that the HRQoL reference values for the outpatient breast clinic population were lower, with more severe symptoms and lower functionality compared to the general population. This suggests that the reference values may not accurately reflect the quality of life of the study population.
Article
Oncology
Mikiyas Amare Getu, Changying Chen, Panpan Wang, Eva Johanna Kantelhardt, Adamu Addissie
Summary: This study aimed to assess the quality of life and its influencing factors among breast cancer patients using a specific questionnaire. The results showed that future perspective had the lowest score, and financial difficulties, appetite loss, and fatigue were the most common symptoms. There were correlations between tumor stage and certain symptoms, and patients without comorbidities had better function in some areas.
Article
Medicine, General & Internal
James W. F. Catto, Pramit Khetrapal, Federico Ricciardi, Gareth Ambler, Norman R. Williams, Tarek Al-Hammouri, Muhammad Shamim Khan, Ramesh Thurairaja, Rajesh Nair, Andrew Feber, Simon Dixon, Senthil Nathan, Tim Briggs, Ashwin Sridhar, Imran Ahmad, Jaimin Bhatt, Philip Charlesworth, Christopher Blick, Marcus G. Cumberbatch, Syed A. Hussain, Sanjeev Kotwal, Anthony Koupparis, John McGrath, Aidan P. Noon, Edward Rowe, Nikhil Vasdev, Vishwanath Hanchanale, Daryl Hagan, Chris Brew-Graves, John D. Kelly
Summary: This study compared the recovery and morbidity of patients undergoing robot-assisted radical cystectomy with intracorporeal reconstruction versus open radical cystectomy for bladder cancer. The results showed that robot-assisted surgery resulted in a statistically significant increase in the number of days alive and out of the hospital within 90 days of surgery. In addition, robot-assisted surgery had lower rates of thromboembolic and wound complications compared to open surgery. Patients who underwent robot-assisted surgery also reported better quality of life and less disability compared to those who underwent open surgery.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Oncology
Laura A. Gray, Monica Hernandez Alava, Allan J. Wailoo
Summary: This study investigates the relationship between EQ-5D-3L and QLQ-C30 in breast cancer patients, providing a mapping model for cost-effectiveness analysis. Using a mixture model, QLQ-C30 scores were successfully converted to EQ-5D-3L scores, offering reliable estimates for economic evaluation of breast cancer health technologies.
Article
Oncology
Ines Vaz-Luis, Antonio Di Meglio, Julie Havas, Mayssam El-Mouhebb, Pietro Lapidari, Daniele Presti, Davide Soldato, Barbara Pistilli, Agnes Dumas, Gwenn Menvielle, Cecile Charles, Sibille Everhard, Anne-Laure Martin, Paul H. Cottu, Florence Lerebours, Charles Coutant, Sarah Dauchy, Suzette Delaloge, Nancy U. Lin, Patricia A. Ganz, Ann H. Partridge, Fabrice Andre, Stefan Michiels
Summary: This study aimed to characterize long-term fatigue trajectories among breast cancer survivors. Three trajectory groups were identified for severe global fatigue, and it was found that different dimensions of fatigue were influenced by different factors. This helps identify patients at increased risk of severe fatigue and inform personalized interventions.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Aishwarya Sunil Kshirsagar, Surendra Kiran Wani
Summary: The study found that patients undergoing chemotherapy after breast cancer surgery were significantly affected in cognitive, social, and physical functions, and reported high levels of pain, fatigue, and insomnia. Many patients expressed concerns about body image, sexual dysfunction, hair loss, chemotherapy side effects, indicating that breast cancer patients face multiple challenges during the chemotherapy process.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
(2021)
Article
Health Care Sciences & Services
Takuya Kawahara, Naruto Taira, Takeru Shiroiwa, Yasuhiro Hagiwara, Takashi Fukuda, Yukari Uemura, Hirofumi Mukai
Summary: This study aimed to establish minimal important differences (MIDs) for the EORTC QLQ-C30 in patients with metastatic breast cancer. Using data from a randomized clinical trial, we estimated MIDs for 8 scales of the QLQ-C30. Patient-reported anchors were found to be more sensitive to early changes in health status.
QUALITY OF LIFE RESEARCH
(2022)
Article
Oncology
Wei-Pang Chung, Hsiang-Lin Song, Chung-Liang Ho, Nan-Tsing Chiu, Wu-Chou Su
JOURNAL OF CLINICAL ONCOLOGY
(2013)
Article
Medicine, General & Internal
Wei-Pang Chung, Kuo-Ting Lee, Ya-Ping Chen, Ya-Ting Hsu, Zhu-Jun Loh, Chien-Chang Huang, Hui-Ping Hsu
Summary: Extremely young breast cancer patients have poorer disease-free survival compared to older patients, but not necessarily poorer overall survival. Tumor size and triple-negative breast cancer are major prognostic factors for poorer disease-free survival in young patients. Aggressive treatment for young patients at early stages of disease can improve survival.
Article
Oncology
Wei-Pang Chung, Wei-Lun Huang, Wei-An Liao, Wan-Ling Huang, You-Yu Liu, Wu-Chou Su
Summary: CK-MB-1 cells represent a stable HER2-positive trastuzumab-resistant breast cancer cell line, and their resistance does not stem from PTEN or the phosphoinositide 3-kinase signaling pathway.
Article
Medicine, General & Internal
Wei-Pang Chung, Chun-Ting Yang, Hsuan-Ying Chen, Ching-Yen Su, Hsin-Wei Su, Huang-Tz Ou
Summary: The study found that for newly-diagnosed metastatic triple-negative breast cancer (mTNBC) patients, first-line single-agent and combination chemotherapies yielded comparable survival outcomes. Younger patients may benefit more from combination regimens, while single-agent chemotherapy may be more suitable for elderly patients.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2022)
Article
Oncology
Zhu-Jun Loh, Kuo-Ting Lee, Ya-Ping Chen, Yao-Lung Kuo, Wei-Pang Chung, Ya-Ting Hsu, Chien-Chang Huang, Hui-Ping Hsu
Summary: This study investigated patients with false-negative sentinel nodes in intraoperative frozen sections (FNSN) and found that patients with larger tumor sizes and more lymphatic tumor emboli have a higher incidence of FNSN. However, the outcomes of FNSN patients after completing axillary lymph node dissection (ALND) were noninferior to those without sentinel node metastasis. ALND provides correct staging for patients with metastasis in nonsentinel axillary lymph nodes.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Wei-Pang Chung, Wei-Lun Huang, Wei-An Liao, Chun-Hua Hung, Chi-Wu Chiang, Chun Hei Antonio Cheung, Wu-Chou Su
Summary: FTY720 can overcome resistance to trastuzumab therapy in patients with HER2-positive breast cancer, showing potential therapeutic effects.
SCIENTIFIC REPORTS
(2022)
Article
Health Care Sciences & Services
Ju Hwan Kim, Chin-Yao Shen, Philip Chun-Ming Au, Yeon-Hee Baek, Ching-Lung Cheung, Wei-Pang Chung, Nora Joelle Kleinman, Tai Chung Lam, Tzu-Chi Liao, Tzu-Chieh Lin, Ju-Young Shin, Chor-Wing Sing, Ian Chi Kei Wong, Edward Chia-Cheng Lai
Summary: This study describes the epidemiology, clinical characteristics, and utilization patterns of bone-targeting agents (BTAs) in patients with bone metastases from breast, prostate, and lung cancer. The findings show that the utilization rate of BTAs remains low in recent years and varies between different regions and tumor types.
BMJ SUPPORTIVE & PALLIATIVE CARE
(2022)
Article
Oncology
Chin-Yao Shen, Philip Chun-Ming Au, Yeon-Hee Baek, Ching-Lung Cheung, Wei-Pang Chung, Ju Hwan Kim, Nora J. Kleinman, Tai-Chung Lam, Tzu-Chi Liao, Tzu-Chieh Lin, Ju-Young Shin, Chor-Wing Sing, Ian Chi Kei Wong, Edward Chia-Cheng Lai
Summary: This study evaluated and compared the treatment persistence and re-initiation with different bone-targeting agents among Asian patients with bone metastases. The results showed that Denosumab had a lower risk of interruption compared to other bisphosphonates in Taiwan and Hong Kong, while Pamidronate had a higher risk of interruption compared to Zoledronic acid in Taiwan and Korea.
Article
Medicine, General & Internal
J. Cortes, S. -B Kim, W. -P Chung, S. -A Im, Y. H. Park, R. Hegg, M. H. Kim, L. -M Tseng, V Petry, C. -F Chung, H. Iwata, E. Hamilton, G. Curigliano, B. Xu, C. -S Huang, J. H. Kim, J. W. Y. Chiu, J. L. Pedrini, C. Lee, Y. Liu, J. Cathcart, E. Bako, S. Verma, S. A. Hurvitz
Summary: Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, trastuzumab deruxtecan was associated with a lower risk of disease progression or death compared to trastuzumab emtansine. However, treatment with trastuzumab deruxtecan was associated with interstitial lung disease and pneumonitis.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Rehabilitation
Wei-Pang Chung, Hsin-Lun Yang, Ya-Ting Hsu, Ching-Hsia Hung, Ping-Yen Liu, Yen-Wen Liu, Shih-Hung Chan, Kun-Ling Tsai
Summary: Previous studies have shown that chemotherapy increases the risk of heart failure, but the cardioprotective effect of real-time exercise in breast cancer patients undergoing chemotherapy is unclear. In this randomized controlled study, 32 women with breast cancer were allocated to either a control group or an exercise group. The exercise group received moderate-to-high-intensity exercise training during chemotherapy and showed better cardiac function and exercise capacity compared to the control group.
ANNALS OF PHYSICAL AND REHABILITATION MEDICINE
(2022)
Article
Oncology
C. E. Geyer, J. E. Garber, R. D. Gelber, G. Yothers, M. Taboada, L. Ross, P. Rastogi, K. Cui, A. Arahmani, G. Aktan, A. C. Armstrong, M. Arnedos, J. Balmana, J. Bergh, J. Bliss, S. Delaloge, S. M. Domchek, A. Eisen, F. Elsafy, L. E. Fein, A. Fielding, J. M. Ford, S. Friedman, K. A. Gelmon, L. Gianni, M. Gnant, S. J. Hollingsworth, S-A Im, A. Jager, S. R. Lakhani, W. Janni, B. Linderholm, T-W Liu, N. Loman, L. Korde, S. Loibl, P. C. Lucas, F. Marme, E. Martinez de Duenas, R. McConnell, K-A Phillips, M. Piccart, G. Rossi, R. Schmutzler, E. Senkus, Z. Shao, P. Sharma, C. F. Singer, T. Spanic, E. Stickeler, M. Toi, T. A. Traina, G. Viale, G. Zoppoli, Y. H. Park, R. Yerushalmi, H. Yang, D. Pang, K. H. Jung, A. Mailliez, Z. Fan, I Tennevet, J. Zhang, T. Nagy, G. S. Sonke, Q. Sun, M. Parton, M. A. Colleoni, M. Schmidt, A. M. Brufsky, W. Razaq, B. Kaufman, D. Cameron, C. Campbell, A. N. J. Tutt, O. Th Johannsson
Summary: The OlympiA trial demonstrated that adjuvant therapy with the oral PARP inhibitor, olaparib, significantly improves overall survival in patients with gBRCA1/2pv-associated early breast cancer. The study also showed improvements in invasive disease-free survival and distant disease-free survival, with no new safety issues identified.
ANNALS OF ONCOLOGY
(2022)
Article
Medicine, General & Internal
Sara A. Hurvitz, Roberto Hegg, Wei-Pang Chung, Seock-Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altintas, Jan-Willem Henning, Giuseppe Curigliano, Jose Manuel Perez-Garcia, Sung-Bae Kim, Vanessa Petry, Chiun-Sheng Huang, Wei Li, Jean-Sebastien Frenel, Silvia Antolin, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortes
Summary: In the DESTINY-Breast03 trial, trastuzumab deruxtecan showed superior progression-free survival compared to trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. The study aimed to compare the efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine. The results demonstrated that trastuzumab deruxtecan had the longest reported median progression-free survival and improved overall survival, reaffirming its role as the standard of care in the second-line setting.
Article
Oncology
Wei-Pang Chung, Chun-Ting Yang, Shuen-Ru Yang, Ching-Yen Su, Hsin-Wei Su, Shang-Yun Liu, Huang-Tz Ou
Summary: This study conducted a large-scale real-world investigation on the clinical outcomes of neoadjuvant treatments for patients with HER2+ and TNBC. The results showed that neoadjuvant trastuzumab significantly improved the pathological complete response (pCR) and overall survival (OS) in HER2+ patients, while platinum-based treatment increased the pCR rate but did not improve OS in TNBC patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Surgery
Zhu-Jun Loh, Kuo-Ting Lee, Wei-Pang Chung, Wen-Chung Chen, Hsueh-Li Kuo, Po-Jun Chen, Hsi-Huei Lu, Hui-Ping Hsu
FORMOSAN JOURNAL OF SURGERY
(2017)